Sanofi-aventis and Regeneron Pharmaceuticals’ Phase III VITAL trial evaluating the investigational drug aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC) showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the primary endpoint of improvement in overall survival compared with docetaxel plus placebo. The addition of aflibercept to docetaxel demonstrated activity in key secondary endpoints of the study: progression free survival (...